Download
s15010-021-01615-8.pdf 705,65KB
WeightNameValue
1000 Titel
  • C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19
1000 Autor/in
  1. Pink, Isabell |
  2. Raupach, David |
  3. Fuge, Jan |
  4. Vonberg, Ralf-Peter |
  5. Hoeper, Marius M. |
  6. Welte, Tobias |
  7. Rademacher, Jessica |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-05-22
1000 Erschienen in
1000 Quellenangabe
  • 49(5):935-943
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s15010-021-01615-8 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140571/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Purpose!#!Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory coronavirus 2 (SARS-CoV-2) has spread around the world. Differentiation between pure viral COVID-19 pneumonia and secondary infection can be challenging. In patients with elevated C-reactive protein (CRP) on admission physicians often decide to prescribe antibiotic therapy. However, overuse of anti-infective therapy in the pandemic should be avoided to prevent increasing antimicrobial resistance. Procalcitonin (PCT) and CRP have proven useful in other lower respiratory tract infections and might help to differentiate between pure viral or secondary infection.!##!Methods!#!We performed a retrospective study of patients admitted with COVID-19 between 6th March and 30th October 2020. Patient background, clinical course, laboratory findings with focus on PCT and CRP levels and microbiology results were evaluated. Patients with and without secondary bacterial infection in relation to PCT and CRP were compared. Using receiver operating characteristic (ROC) analysis, the best discriminating cut-off value of PCT and CRP with the corresponding sensitivity and specificity was calculated.!##!Results!#!Out of 99 inpatients (52 ICU, 47 Non-ICU) with COVID-19, 32 (32%) presented with secondary bacterial infection during hospitalization. Patients with secondary bacterial infection had higher PCT (0.4 versus 0.1 ng/mL; p = 0.016) and CRP (131 versus 73 mg/L; p = 0.001) levels at admission and during the hospital stay (2.9 versus 0.1 ng/mL; p < 0.001 resp. 293 versus 94 mg/L; p < 0.001). The majority of patients on general ward had no secondary bacterial infection (93%). More than half of patients admitted to the ICU developed secondary bacterial infection (56%). ROC analysis of highest PCT resp. CRP and secondary infection yielded AUCs of 0.88 (p < 0.001) resp. 0.86 (p < 0.001) for the entire cohort. With a PCT cut-off value at 0.55 ng/mL, the sensitivity was 91% with a specificity of 81%; a CRP cut-off value at 172 mg/L yielded a sensitivity of 81% with a specificity of 76%.!##!Conclusion!#!PCT and CRP measurement on admission and during the course of the disease in patients with COVID-19 may be helpful in identifying secondary bacterial infections and guiding the use of antibiotic therapy.
1000 Sacherschließung
gnd 1206347392 COVID-19
lokal Secondary bacterial infections
lokal Humans [MeSH]
lokal Procalcitonin
lokal Retrospective Studies [MeSH]
lokal COVID-19
lokal Antimicrobial Stewardship [MeSH]
lokal COVID-19 / SARS-CoV-2
lokal Antimicrobial stewardship
lokal Procalcitonin [MeSH]
lokal ROC Curve [MeSH]
lokal COVID-19 [MeSH]
lokal Original Paper
lokal C-Reactive Protein/analysis [MeSH]
lokal Biomarkers [MeSH]
lokal C-reactive protein
lokal SARS-CoV-2 [MeSH]
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/UGluaywgSXNhYmVsbA==|https://frl.publisso.de/adhoc/uri/UmF1cGFjaCwgRGF2aWQ=|https://frl.publisso.de/adhoc/uri/RnVnZSwgSmFu|https://frl.publisso.de/adhoc/uri/Vm9uYmVyZywgUmFsZi1QZXRlcg==|https://frl.publisso.de/adhoc/uri/SG9lcGVyLCBNYXJpdXMgTS4=|https://frl.publisso.de/adhoc/uri/V2VsdGUsIFRvYmlhcw==|https://frl.publisso.de/adhoc/uri/UmFkZW1hY2hlciwgSmVzc2ljYQ==
1000 Hinweis
  • DeepGreen-ID: 9e041f32c2354d3c96627172b3a31303 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6444046.rdf
1000 Erstellt am 2023-04-27T11:48:10.429+0200
1000 Erstellt von 322
1000 beschreibt frl:6444046
1000 Zuletzt bearbeitet Fri Oct 20 11:54:37 CEST 2023
1000 Objekt bearb. Fri Oct 20 11:54:37 CEST 2023
1000 Vgl. frl:6444046
1000 Oai Id
  1. oai:frl.publisso.de:frl:6444046 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source